Caprock Group LLC Lowers Holdings in DexCom, Inc. (NASDAQ:DXCM)

Caprock Group LLC cut its position in DexCom, Inc. (NASDAQ:DXCM) by 59.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 3,503 shares of the medical device company’s stock after selling 5,092 shares during the quarter. Caprock Group LLC’s holdings in DexCom were worth $235,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Advisors Asset Management Inc. raised its holdings in DexCom by 13.9% in the 1st quarter. Advisors Asset Management Inc. now owns 14,800 shares of the medical device company’s stock worth $2,053,000 after acquiring an additional 1,809 shares during the last quarter. Ascent Group LLC lifted its holdings in shares of DexCom by 3.7% during the first quarter. Ascent Group LLC now owns 6,295 shares of the medical device company’s stock valued at $873,000 after purchasing an additional 222 shares in the last quarter. Kennedy Capital Management LLC purchased a new stake in shares of DexCom during the first quarter valued at $1,690,000. B. Riley Wealth Advisors Inc. increased its holdings in DexCom by 132.0% in the 1st quarter. B. Riley Wealth Advisors Inc. now owns 3,766 shares of the medical device company’s stock worth $522,000 after buying an additional 2,143 shares in the last quarter. Finally, California State Teachers Retirement System increased its holdings in DexCom by 0.6% in the 1st quarter. California State Teachers Retirement System now owns 615,429 shares of the medical device company’s stock worth $85,360,000 after buying an additional 3,500 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insider Transactions at DexCom

In related news, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The trade was a 0.56 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,431 shares of company stock valued at $399,319 over the last 90 days. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on DXCM. Piper Sandler reaffirmed an “overweight” rating and set a $90.00 price target on shares of DexCom in a report on Monday, August 26th. Sanford C. Bernstein lifted their target price on shares of DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Robert W. Baird boosted their target price on shares of DexCom from $80.00 to $82.00 and gave the company a “neutral” rating in a research note on Monday, August 5th. Oppenheimer dropped their price target on DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research note on Friday, October 25th. Finally, Wells Fargo & Company increased their target price on DexCom from $80.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Trading Down 2.2 %

Shares of DexCom stock opened at $72.83 on Monday. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46. The company has a market capitalization of $28.45 billion, a P/E ratio of 43.61, a P/E/G ratio of 2.28 and a beta of 1.17. The company has a fifty day moving average of $70.61 and a 200 day moving average of $89.55.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.